We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Evofem Biosciences Inc | NASDAQ:EVFM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.4782 | 0.465 | 0.468 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
|
||
WASHINGTON, D.C. 20549
|
||
SCHEDULE 13D
|
||
(AMENDMENT NO. 7)
|
||
UNDER THE SECURITIES ACT OF 1934
|
||
Evofem Biosciences, Inc.
|
||
(Name of Issuer)
|
||
Common Stock, $0.0001 par value per share
|
||
(Title and Class of Securities)
|
||
30048L104
|
||
(CUSIP Number)
|
||
Robert Leveille
|
||
Invesco Ltd.
|
||
1555 Peachtree Street, N.E., Suite 1800
|
||
Atlanta, Georgia 30309
|
||
Telephone number: (404) 892-0896
|
||
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
|
||
April 22, 2021
|
||
(Date of Event which Requires Filing of this Statement)
|
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ◻
(b) ◻ |
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS
OO
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
|
2(d) ◻
OR
2(e) ◻
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
|
|||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7
|
SOLE VOTING POWER
8,698,775
|
||
8
|
SHARED VOTING POWER
0
|
|||
9
|
SOLE DISPOSITIVE POWER
8,698,775
|
|||
10
|
SHARED DISPOSITIVE POWER
0
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,698,775(1)
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ◻
|
|||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.4%(2)
|
|||
14
|
TYPE OF REPORTING PERSON
HC, IA
|
|||
(1) Includes presently exercisable warrants to purchase 555,556
shares of the Issuer’s Common Stock.
(2) Based on total outstanding shares of 103,393,874, consisting of
83,124,033 shares as reported by the Issuer in its proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 29, 2021, 19,714,285 shares issued pursuant to a public offering on March 29, 2021 (including
2,571,428 shares issued pursuant to an underwriters' option) and 555,556 shares issuable upon exercise of warrants owned by the Reporting Person.
|
Dated: April 27, 2021
|
||
INVESCO LTD.
|
||
By:
|
/s/ Robert R. Leveille
|
|
Name: Robert R. Leveille
|
||
Title: Global Assurance Officer
|
Trade Date
|
Fund
|
Buy/Sell
|
Shares
|
Price Per Share
|
4/13/2021
|
Truist International Developed Growth Index Trust
|
Buy
|
2,135
|
1.67
|
4/22/2021
|
Invesco UK Equity High Income Fund (UK)
|
Sell
|
256,455
|
1.52(1)
|
4/22/2021
|
Invesco UK Equity Income Fund (UK)
|
Sell
|
157,142
|
1.52(1)
|
4/23/2021
|
Invesco UK Equity High Income Fund (UK)
|
Sell
|
458,416
|
1.50(2)
|
4/23/2021
|
Invesco UK Equity Income Fund (UK)
|
Sell
|
280,892
|
1.50(2)
|
1 Year Evofem Biosciences Chart |
1 Month Evofem Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions